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Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a causative gene for
Parkinson’s disease, but the physiological function and the
mechanism(s) by which the cellular activity of LRRK2 is regulated
are poorly understood. Here, we identiﬁed p21-activated kinase 6
(PAK6) as a novel interactor of the GTPase/ROC domain of
LRRK2. p21-activated kinases are serine-threonine kinases that
serve as targets for the small GTP binding proteins Cdc42 and
Rac1 and have been implicated in different morphogenetic
processes through remodeling of the actin cytoskeleton such as
synapse formation and neuritogenesis. Using an in vivo neuro-
morphology assay, we show that PAK6 is a positive regulator of
neurite outgrowth and that LRRK2 is required for this function.
Analyses of post-mortem brain tissue from idiopathic and LRRK2
G2019S carriers reveal an increase in PAK6 activation state,
whereas knock-out LRRK2mice display reducedPAK6 activation
and phosphorylation of PAK6 substrates. Taken together, these
results support a critical role of LRRK2 GTPase domain in
cytoskeletal dynamics in vivo through the novel interactor PAK6,
and provide a valuable platform to unravel the mechanism
underlying LRRK2-mediated pathophysiology.
Keywords: LRRK2, neurodegeneration, neuronal cyto-
skeleton, p21-activated kinases, Parkinson’s disease.
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ROCO proteins constitute a family of proteins with a Ras-
like domain, termed ras of complex (ROC), which is always
followed by a C-terminus Of ROC (COR) domain of unclear
function (Bosgraaf and Van Haastert 2003). Humans possess
four ROCOs, namely leucine-rich repeat kinase 1 (LRRK1),
leucine-rich repeat kinase 2 (LRRK2), death-associated
protein kinase 1 (DAPK1), and malignant ﬁbrous histiocy-
toma-ampliﬁed sequences with leucine-rich tandem repeats 1
(MASL1) (Lewis 2009; Civiero et al. 2014). Human ROCOs
are capable of binding guanine nucleotides via their ROC
domain and nucleotide binding seems important for complex
formation and kinase activity (Lewis et al. 2007; Jebelli
et al. 2012; Biosa et al. 2013; Dihanich et al. 2013),
suggesting that this domain is a central hub in ROCO
function. Although ROCO proteins have been formally
described over 10 years ago, their cellular functions remain
elusive as well as the mechanisms by which these proteins,
together with other signaling molecules, regulate cellular
processes.
Special interest has been directed at understanding the
cellular functions of LRRK2, given that mutations in this
gene are a common cause of Parkinson’s disease (PD)
(Paisan-Ruiz et al. 2004, 2008; Zimprich et al. 2004).
LRRK2 has been linked with several pathways relevant for
neuronal physiology, including autophagy (Plowey et al.
2008; Gomez-Suaga et al. 2012; Manzoni et al. 2013),
vesicle trafﬁcking (Piccoli et al. 2011; MacLeod et al. 2013;
Cirnaru et al. 2014), neurite outgrowth (MacLeod et al.
2006; Dachsel et al. 2010; Winner et al. 2011), cytoskeletal
dynamics (Kett et al. 2011; Caesar et al. 2013, 2015; Habig
et al. 2013; Law et al. 2013), and inﬂammation (reviewed in
Russo et al. 2014). Although some of these functions may
appear unrelated, they all rely on the presence of a functional
cytoskeleton. Vesicles trafﬁc via the cytoskeleton, neurite
growth is dynamically balanced between the opposing
actions of microtubules and F-actin, and activated macro-
phages migrate via ﬁlopodia and membrane blebs (Ma and
Baumgartner 2013).
LRRK2 is a large and complex molecule that contains
serine-threonine kinase and GTPase activities (Greggio 2012;
Taymans 2012). Kinase activity has been intensively studied,
as there is great interest in identifying therapies for PD and
kinases are ideal targets. To date, a number of LRRK2
putative substrates have been identiﬁed (Matta et al. 2012;
Yun et al. 2013; Martin et al. 2014) but the most consis-
tently reported is LRRK2 itself. LRRK2 undergoes
autophosphorylation in vitro (Greggio and Cookson 2009)
and in vivo (Sheng et al. 2012), possibly acting as an
intramolecular regulator of ROC by phosphorylating serine-
threonine residues important for nucleotide binding (Greggio
et al. 2009; Webber et al. 2011; Greggio 2012; Taymans
2012), thus positioning ROC as the signaling output of
LRRK2 activity. However, heterologous effectors of ROC
similar to Ras effector kinases for Ras GTPases have not yet
been reported.
Here, starting from an unbiased protein array screen we
identiﬁed p21-activated kinase 6 (PAK6) as a potential
binding partner for LRRK2 (Beilina et al. 2014). We found
that the GTPase/ROC domain of LRRK2 binds the Cdc42/
Rac-interactive binding (CRIB) domain of PAK6. Function-
ally, LRRK2 is required for PAK6 activation monitored by
autophosphorylation of threonine 560 and PAK6-dependent
neurite outgrowth in mouse brain. Related to disease, we
found that PAK6 is hyperactivated in G2019S and idiopathic
PD (iPD) post-mortem brains compared to healthy controls,
highlighting PAK6 as a novel pharmacological target in PD.
Materials and methods
Animals
C57BL/6 LRRK2 wild-type and knock-out mice were provided by
Dr. Heather Melrose and Jackson Laboratory [B6.129X1(FVB)-
Lrrk2tm1.1Cai/J]. Housing and handling of mice were done in
compliance with national guidelines. All animal procedures were
approved by the Ethical Committee of the University of Padova and
the Italian Ministry of Health (license 46/2012), and by the
Institutional Care and Use Committee of KU Leuven.
Plasmids
Eukaryotic expression constructs of 3xFlag tagged LRRK2 (wild
type, K1906M and G2019S), and LRRK2 domains (in pCHMWS-
3xFlag vectors) were generated as described previously (Lobbestael
et al. 2010; Daniels et al. 2011; Civiero et al. 2012). The
pDONR223-PAK6 (plasmid 23833, Johannessen et al. 2010) was
obtained from Addgene (Cambridge, MA, USA). PAK cDNA
sequences in pDONR223 were cloned by LR Clonase-mediated
gateway recombination (Life Technologies, Grand Island, NY,
USA) into the destination vector pCMV-Tag3B-2xMyc modiﬁed
with a gateway cassette as previously described (Greggio et al.
2007). Full-length PAK6 was ampliﬁed from pDONR223-PAK6
with the following primers: forward 50-GGTGCGGC
CGCGATGTTCCGCAAGAAAAAG-30 and reverse 50-GGTTCTA
GATCAGCAGGTGGAGGTCTG-30 that introduced NotI and XbaI
restriction sites at the 50 and 30 ends of the PCR fragment,
respectively. The PCR fragment was puriﬁed, cleaved with NotI/
XbaI and cloned into 3xFlag-cytomegalovirus (CMV) vector
(Sigma, St Louis, MO, USA). Mutant variants were generated
using the Quick-Change II site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA).
For lentiviral vector (LV) construction, cDNA sequences encod-
ing PAK6 wild type, K436M and S531N were ampliﬁed by PCR
using oligonucleotides that introduced XbaI/XbaI restriction
sites (forward 50-GGTTCTAGAATGTTCCGCAAGAAAAAG-30;
reverse 50- GGTTCTAGATCAGCAGGTGGAGGTCTG-30) and
subcloned into the lentiviral transfer backbone pCHMWS-3xFlag-
MCS-ires-eGFP (Ibrahimi et al. 2009).
To produce stable cell lines over-expressing PAK6 wild type, the
cDNA sequence was ampliﬁed by PCR using oligonucleotides that
introduce ClaI/XbaI restriction sites (forward 50-GGTATCGATAC
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CATGTTCCGCAAGAAAAAG-30; reverse 50- GGTTCTAGATC
AGCAGGTGGAGGTCTG-30 and subcloned into the lentiviral
transfer plasmid pCHMWS-MCS-ires-hygro.
To subclone PAK6 into the adeno-associated viral transfer
plasmid pAAV-TF-CMV-GFP-MCS, cDNA sequences encoding
3xFlag-PAK6 wild type, K436M and S531N were ampliﬁed using
oligonucleotides that introduce AgeI/XbaI restriction sites (forward
50-AAAAAAACCGGTGCCACCATGGACTACAAAGACCATG
A-30; reverse 50-AAAAAATCTAGATCAGCAGGTGGAGG-30).
The GFP sequence was excised from pAAV-TF-CMV-GFP (Tay-
mans et al. 2007) and the 3xFlag-PAK6 cDNA fragments were
inserted.
For glutatione S-transferase (GST) pull-down assay, the nucleo-
tide sequence encoding CRIB was cloned into a pGEX-4T bacterial
vector. Two sets of primers with complementary overhangs
encoding the CRIB sequence and containing EcoRI/XhoI restriction
sites (forward A 50- AATTCACATGGAGATCTCAGCGCCACA-
GAACTTCCAGCACCGTGTCCACACCTCCT-30; reverse A 50-
GGTCGAAGGAGGTGTGGACACGGTGCTGGAAGTTCTGTG
GCGCTGAGATCTCCATGTG-30; forward B 50- TCGACCC-
CAAAGAAGGCAAGTTTGTGGGCCTCCCCCCACAATGGCA
GAACATCCTGGACTGAC-30; reverse B 50- TCGAGTCAGTC
CAGGATGTTCTGCCATTGTGGGGGGAGGCCCACAAACTTG
CCTTCTTTGG-30) were annealed, phosphorylated, and subse-
quently cloned. All plasmids were veriﬁed by restriction analysis
and DNA sequencing.
Cell cultures and transfection
HEK293T cells were purchased from Life technologies and cultured
in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
fetal bovine serum. Cell lines, were maintained at 37°C and in a 5%
CO2 controlled atmosphere. HEK293T were transfected with
plasmid DNA using polyethylenimine (Polysciences, Warrington,
PA, USA) according to the manufacturer’s recommendations.
Viral vector production and transduction
All experiments involving viral vectors were carried out under
biosafety level 2 conditions. Housing and handling of mice were
done in compliance with national guidelines; all animal procedures
were approved by the Institutional Care and Use Committee of the
KU Leuven.
LV and recombinant adeno-associated viral vectors (rAAV2/7)
encoding mCherry-GFP, human 3xFlag-PAK6 wild type, K436M
and S531N under control of the CMV promoter were produced by
the Leuven Viral Vector Core as described previously (Lobbestael
et al. 2010; Van der Perren et al. 2011). For transduction of mouse
striata, eight-week-old male C57bL/6 mice were used for rAAV-
3xFlag-PAK6 injections. Animals were anaesthetized and placed in
a stereotactic head frame. After making a midline incision of the
scalp, a burr hole was drilled in the appropriate location at one or
both sites of the skull using Bregma as reference. The following
coordinates were used: anteroposterior 0.5 mm; lateral 2.0 mm;
dorsoventral 3.0 mm. Two microliters of rAAV vectors (titers
ranging from 1.5 to 3.8 9 1012 genome copies/mL) were injected
unilaterally in mouse striatum at a rate of 0.25 lL/min with a 30-
gauge needle on a 10-lL Hamilton syringe. After injection, the
needle was left in place for additional 5 min before being slowly
withdrawn from the brain. Two weeks later, animals were deeply
anesthetized using an overdose of pentobarbital. For immunohisto-
chemistry, animals were transcardially perfused with saline solution
followed by ice-cold 4% paraformaldehyde in phosphate-buffered
saline. The brain was removed from the skull and post-ﬁxed
overnight in 4% paraformaldehyde-phosphate-buffered saline at
4°C. Sections (50 lm) were stained using rabbit anti-ﬂag antibody
(Sigma) as previously described (Lobbestael et al. 2010). The mean
percentage of the transduced striatal area is calculated by measuring
the transduced striatal area/total striatal area every ﬁve sections of
the mouse striatum. Alternatively, the striata were dissected,
homogenized, and subjected to western blot analysis, as described
in (Taymans et al. 2006).
Antibodies
For immunoblotting analysis the following antibodies were used:
rabbit LRRK2 MJFF2 (Cat# 3514-1, RRID:AB_10643781, 1 : 100;
Epitomics), rabbit LRRK2 phospho-S935 (Cat# 5099-1, RRID:AB_
11132319, 1 : 100; Epitomics, Cambridge, UK), rabbit LRRK2
phospho-T2483 (Cat#156577, 1 : 2000; Abcam, Cambridge, UK),
rabbit LRRK2 phospho-T1491 (Cat#140106, 1 : 2000; Abcam,
Cambridge, UK), mouse Flag M2 (Cat# F1804, 1 : 10000; Sigma),
mouse c-Myc 9E10 (Cat# 11667149001, RRID:AB_ 390912,
1 : 5000; Roche Molecular Biochemicals, Indianapolis, IN, USA),
rabbit PAK6 (Cat# HPA031124, RRID:AB_10601044, 1 : 2000,
Prestige; Sigma), mouse b-tubulin (Cat# T8328, RRID:
AB_1844090, 1 : 5000; Sigma), rabbit phospho-PAK4-5-6 (Cat#
SAB4504052, 1 : 2000; Sigma), rabbit phospho-LIM domain kinase
1 (LIMK1) (Cat#3841, 1 : 1000; Cell Signaling Technology, Bev-
erly, MA, USA), mouse LIMK1 (Cat#117623, 1 : 1000; Abcam).
For immunoprecipitation, the following antibodies were used:
rabbit LRRK2 UDD3 (Cat# 5097-1, 1 lg/mg total proteins;
Epitomics), mouse c-Myc (9E10, Cat# 11667149001, RRID:
AB_390912, 0.8 lg/mg total proteins; Roche), mouse Flag M2
(Cat# F1804, 1 lg/mg total proteins; Sigma).
Immunohistochemistry and confocal imaging
For the in vivo experiments on striatal neurons of normal and
LRRK2 knock-out mice expressing 3xFlag-PAK6 variants (or
Table 1 Sample demographics of the human cases used in this study
Case
Sex
M/F
Age
(years)
PM
Delay (h) pH of tissue WB/IH
G2019S1 F 80 44.4 6 WB &IH
G2019S2 F 81 15 6.53 WB
G2019S3 F 84 32.2 5.79 WB&IH
G2019S4 F 72 24.55 6.2 WB&IH
iPD1 M 70 61.2 6.29 WB&IH
iPD2 F 87 47.45 6.62 WB&IH
iPD3 M 75 48 6.0 WB
iPD4 F 88 11.3 6.38 WB&IH
Control 1 F 85 37 6.4 WB&IH
Control 2 F 91 98.5 6.26 WB&IH
Control 3 M 87 36 6.1 WB&IH
Control 4 F 68 41.5 5.98 WB
AD M 82 38 N/A IH
iPD, idiopathic PD; N/A, not available.
© 2015 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2015) 135, 1242--1256
1244 L. Civiero et al.
mCherry control) and labeled for eGFP to study morphology,
sections were analyzed by immunohistochemistry to detect eGFP
and PAK6 or mCherry expressing neurons. Sections were incubated
with rabbit anti-eGFP and mouse anti-ﬂag antibody as described in
Lobbestael et al. (Lobbestael et al. 2010). Labels were revealed
with ﬂuorescent secondary antibodies (anti-rabbit-alexa-488 and
anti-mouse-alexa-555) and visualized by confocal microscopy. First
eGFP-labeled striatal neurons were conﬁrmed to co-express PAK6
variants or the mCherry control. Next, z-stacks were taken of the
conﬁrmed neurons. 2D projections derived from these z-stacks were
submitted to neurite complexity analysis using the NeuronJ plugin
in ImageJ (Meijering et al. 2004).
Co-immunoprecipitation and western blotting
Cells were harvested at 48 h post transfection and lysed in buffer
containing 50 mM Tris pH 7.5, 1% Triton X-100, 1 mM sodium
orthovanadate, 5 mM sodium pyrophosphate, 50 mM sodium
ﬂuoride, 0.27 M sucrose, 1 mM EDTA). Lysates were incubated
with primary antibody overnight then with Protein-G Sepharose for
1 h or with primary antibody directly conjugated to agarose beads.
Immunocomplexes were washed three times with lysis buffer
supplemented with 0.25 M NaCl. Immunoprecipitates were resus-
pended in sample buffer.
Between 10 and 20 lg of protein samples were resolved on 4-20%
Tris-glycine polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA,
USA) in sodium dodecyl sulfate/Tris-glycine running buffer or on
NuPAGE 3–8% Tris-acetate Gel (Life Technologies). Precision Plus
molecular weight markers (Bio-Rad) were used for size estimation.
Resolved proteinswere transferred to polyvinylidene diﬂuoride (PVDF)
membranes in transfer buffer containing 10% methanol. The PVDF
sheets were blocked in Tris-buffered saline plus 0.1% Triton (TBS-T)
plus 5% non-fat dry milk for 1 h at 4°C and then incubated overnight at
4°C with anti-Flag-M2 antibody in TBS-T plus 5% non-fat dry milk.
The PVDF membranes were washed in TBS-T (3 9 10 min) at RT
followed by incubation for 1 h at RT with horseradish peroxidase-
conjugated anti-mouse IgG. Blots were then washed in TBS-T
(4 9 10 min) at RT and rinsed in TBS, and immunoreactive proteins
were visualized using enhanced chemiluminescence plus (GE Health-
care, Little Chalfont, England). Densitometric analysis was carried out
using Image J software (Schneider et al. 2012).
Pull-down assay
GST-tagged proteins were expressed and puriﬁed from BL21
bacterial cells (as described in Greggio et al. 2009); 3xFlag-tagged
proteins were expressed in HEK293T cell lines as previously
described (Civiero et al. 2012). Puriﬁed proteins bound to the resin
were incubated for 2 h with cell lysates over-expressing the prey
protein. For the following procedure see co-immunoprecipitation
and western blotting section.
In vitro kinase reactions
Kinase assays were carried out as previously described (Civiero
et al. 2012; Jebelli et al. 2012). Protein concentrations used are
indicated in ﬁgure legends.
Post-mortem human tissues analysis
Post-mortem human tissue samples were obtained from Queen
Square Brain Bank (London, UK). Sample demographics are listed
in Table 1. The 5% sodium dodecyl sulfate fractions from the basal
ganglia from three G2019S LRRK2 mutation cases, four matched
iPD cases and four control cases were prepared according to the
methods described in Mamais et al. (Mamais et al. 2013). 40 lg of
proteins was loaded onto 12% Tris-Glycine gels (Bio-Rad) and
transferred onto PVDF membrane. The membranes were probed
with primary antibodies at 1 : 1000 dilution (phospho-S602/560
antibody Sigma Cat no SAB4504722; PAK-6 Sigma Cat no
HPA031124). Immunohistochemistry with PAK phospho-S602/
560 antibody was performed on formalin ﬁxed wax-embedded
slides. Brieﬂy, sections 8-lm-thick were dewaxed in xylene,
blocked for endogenous peroxidase with H2O2 (0.3%) containing
methanol followed by pressure-cooking in citrate buffer pH 7.0 for
10 min to reveal antigenic sites. The sections were then blocked in
10% non-fat milk for an hour at 23C followed by incubation in
primary antibody at 1 : 100 dilution o/n at 4°C. Following washes,
sections were treated with anti-rabbit biotynilated secondary anti-
body (1 : 200, 30 min; Dako, Carpinteria, CA, USA) followed by
treatment with ABC reagent (Vector Laboratories, Burlingame, CA,
USA) for 30 min and visualizing with H2O2-activated diaminoben-
zidine as chromogen. Sections are counter-stained lightly with
Mayer’s hematoxylin, taken through graded ethanols and xylene and
mounted with coverslips with DPX (VWR, International PBI,
Milano, Italy) mounting medium.
A four-tired grading system was used to provide a
semi-quantitative assessment of P-PAK immunoreactivity (IR) in
basal ganglia. Assessment was by consensus between two
observers. Score 0 = no P-PAK IR, score + = weak P-PAK
IR, score ++ = moderate P-PAK IR, score +++ = strong P-PAK
IR.
Statistical analysis
All quantitative data are expressed as mean  SD (standard error)
or SEM (standard error of the mean) and represent at least three
independent sets of experiments. Signiﬁcance of differences
between two groups was assessed by unpaired t-test or by one-
way ANOVA with Tukey’s post hoc test and two-way ANOVA with
Tukey’s HSD post hoc test when more than two groups were
compared. Signiﬁcance level was set at p < 0.05.
Results
LRRK2 interacts with PAK6
In a previous study, we reported high conﬁdence interactors
of LRRK2 identiﬁed by probing protoarrays with full-
length recombinant LRRK2 protein (Beilina et al. 2014;
Reyniers et al. 2014). We repeated this experiment with
puriﬁed full-length LRRK2 alone or with additional GDP
and non-hydrolysable GTP (Guanosine-50-[(b,c)-methyleno]
triphosphate, GppCp) and used a Z-score of 3 (i.e., 3
standard deviations from background) as a cutoff for
candidate interactions. Together with known interactors
including 14-3-3 proteins (Dzamko et al. 2010; Nichols
et al. 2010) and cyclin G-associated kinase (Beilina et al.
2014), the protoarray experiment identiﬁed p21-activated
kinase 6 (PAK6) as a potential LRRK2 interactor with
higher interaction in the presence of GppCp (Z scores: apo-
© 2015 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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LRRK2 3.93, GDP-LRRK2 3.07, and GppCp-LRRK2 6.56;
Fig. 1a). Of the members of the PAK family (PAK2,
PAK3, and two PAK4 transcript variants) spotted on the
arrays, only PAK6 showed Z scores above the threshold of
3. PAK6 kinase domain alone also spotted on the array did
not give signiﬁcant signal (Fig. 1a). These results suggest
© 2015 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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that full-length PAK6 is required to observe interaction with
LRRK2.
PAK6 belongs to group II p21-activated kinases (PAKs), a
family of proteins involved in cell remodeling pathways via
regulation of actin cytoskeleton dynamics (Szczepanowska
2009), processes where also LRRK2 has been implicated
(Meixner et al. 2011; Habig et al. 2013; Caesar et al. 2015).
We therefore pursued the hypothesis of PAK6 as a potential
interactor with, and mediator of the biological effects of,
LRRK2. We ﬁrst performed co-immunoprecipitation to
conﬁrm the interaction. In HEK293T cells, 2xMyc-PAK6
was co-immunoprecipitated with 3xFlag-LRRK2 (Fig. 1b)
and 3xFlag-LRRK2 could be reciprocally co-immunoprecip-
itated by 2xMyc-PAK6 (Fig. 1c). Under these conditions, we
recovered ~ 3.5-fold more LRRK2 protein bound to 2xMyc-
PAK6 than to 2xMyc-14-3-3 zeta (Fig. 1d). We subse-
quently tested the interaction between the two endogenous
kinases in mouse brain. LRRK2 immunoprecipitated from
wild-type mouse brain efﬁciently co-puriﬁes PAK6, whereas
no PAK6 is detected in knock-out lysates incubated with
anti-LRRK2 antibodies (Fig. 1e). As negative control, we
did not observe interaction with Rab3A. In addition, ectopic
expression of LRRK2 and PAK6 in primary cortical neurons
results in co-localization of the two kinases in the soma and
dendrites with both diffuse and spotted distribution (Fig. 1f).
We then dissected the interaction down to domain level.
PAK6 interactedwith constructs containing theROCandROC-
COR, but not COR domain, of LRRK2 (Fig. 2a–b). As we had
observed that the interaction is modulated by guanine
nucleotides in protoarrays and involves the ROC domain of
LRRK2,we hypothesized that PAK6 interacts with LRRK2 via
its CRIB domain, a conserved sequence near the N-terminus
(Fig. 2c) involved in the binding of small GTPase such as
Cdc42 andRac1 (Thompson et al. 1998) (PDB-ID: 2ODB). To
test this, we performed a pull-down assay generally used to
isolate active small GTPases such asRac1.As a control, weﬁrst
incubated GST-tagged CRIB bound to glutathione-sepharose
beadswith cell lysates fromHEK293T cells expressing 3xFlag-
Rac1 in the presence of GDP or GppCp. As expected, Rac1
strongly binds PAK6 GST-CRIB when activated with non-
hydrolysable GTP (Fig. 2d–f). We then performed the exper-
iment using lysates from HEK293T transfected with 3xFlag-
LRRK2. GST-CRIB pulls-down LRRK2 protein and displays
increased interaction for the kinase in the presence of non-
hydrolyzable nucleotides (Fig. 2e–f).
These data indicate that LRRK2 and PAK6 interact
through ROC and CRIB domain, respectively, in a guanine
nucleotide-dependent fashion.
PAK6 induces neurite outgrowth in a manner dependent on
its kinase activity and LRRK2
We next asked whether LRRK2-PAK6 interaction might
have functional consequences in neurons. PAKs play a
central role in dendrite development, contributing to branch-
ing and spine formation by modulating actin and microtubule
dynamics in a kinase-dependent manner (Eswaran et al.
2008). Double PAK5/6 knock-out mice display a decreased
number of neuronal processes, locomotor changes, and
memory deﬁcits (Nekrasova et al. 2008). Similarly, LRRK2
has an established role in regulating neurite outgrowth
(MacLeod et al. 2006; Dachsel et al. 2010; Sepulveda et al.
2013). To investigate a putative role of LRRK2 and PAK6 in
regulating neuronal morphology in vivo, we measured the
effect of PAK6 expression on neurite length in LRRK2 wild-
type versus knock-out mouse striatum.
First, the interaction between over-expressed PAK6 and
endogenous LRRK2 was assessed in our paradigm. rAAV2/7
vectors expressing 3xFlag-PAK6 wild type or 3xFlag-GFP
were unilaterally injected in the striatum of 3-month-old
C57bL/6 mice and 15 days post injection, transgene expres-
sion and spreading were conﬁrmed by immunohistochem-
istry and western blotting analysis (Fig. 3a). PAK6
immunoprecipitated from dissected striata interacted strongly
with endogenous LRRK2, whereas Flag immunoprecipita-
tions of GFP-expressing striatum or non-injected striatum
failed to co-immunoprecipitate LRRK2 (Fig. 3b).
Fig. 1 PAK6 interacts with LRRK2. (a) Plot of Z-score (y-axis) for
selected bait proteins (x-axis; 14-3-3 zeta and cyclin G-associated
kinase (GAK) are positive controls) for arrays probed with GFP (stars),
LRRK2 alone (ﬁlled black dots), LRRK2 in the presence of GDP (empty
black dots) and LRRK2 in the presence of Guanosine-50-[(b,c)-
methyleno]triphosphate (GppCp) (empty black triangles). The dotted
horizontal line indicates Z = 3 used as a cutoff for identifying candidate
hits. Note that, outside of the positive control proteins, only full-length
PAK6 is above the threshold line. (b) PAK6 co-immunoprecipitates
with LRRK2 in vitro. Cell lysates from HEK293T cells co-transfected
with Flag-LRRK2 and Myc-PAK6 or Myc-14-3-3 were subjected to co-
immunoprecipitation with anti-Flag, followed by anti-Myc and anti-Flag
immunoblotting. As negative control, cell lysates co-transfected with
Flag-GFP and Myc-PAK6 or Myc-14-3-3 were subjected to the same
protocol. (c) Cell lysates from HEK293T cells co-transfected with Flag-
LRRK2 and Myc-PAK6 or Myc-1433 were subjected to co-immuno-
precipitation with anti-myc, followed by anti-Myc and anti-Flag
immunoblotting. As negative control, cell lysates co-transfected with
Flag-LRRK2 and empty vector (EV) were subjected to the same
protocol. (d) Quantiﬁcation of LRRK2 binding to PAK6 and 14-3-3.
Data are representative of three independent experiments and bars
represent the mean  SEM relative to 14-3-3. (e) PAK6 interacts with
LRRK2 in vivo. Endogenous LRRK2 was immunoprecipitated from
wild-type and LRRK2 knock-out brain lysates as control using anti-
LRRK2 antibody. Samples were analyzed by immunoblotting using
anti-PAK6 and anti-LRRK2. (f) PAK6 and LRRK2 co-localize in
neurons. Primary cortical neurons were transfected with Flag-LRRK2
and Myc-PAK6 and then subjected to immunocytochemistry tech-
niques using anti-Flag (green) and anti-PAK6 (red) antibodies. * and **
indicate antibody chains
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To explore the impact of PAK6 kinase activity in
regulating neuronal branching, we then generated PAK6
kinase dead (K436M) and hyper-active (S531N) mutants
(Fig. 4a) (Schrantz et al. 2004). As readout of PAK6 kinase
activity in our experimental model, we monitored the
autophosphorylation of PAK6 at S560, a site conserved
among PAK4/5/6 and analogous to T423 of PAK1, known to
play a pivotal role in regulating the activity and function of
PAK6 (Qu et al. 2001). As expected, PAK6 K436M is
devoid of autophosphorylation activity, whereas PAK6
S531N is ~ 2-fold more active than its wild-type counterpart
(Fig. 4a–b) (*p < 0.05 PAK6 wild type vs. S531N, unpaired
t-test).
Then, rAAV encoding mCherry control, 3xFlag-PAK6
wild type, 3xFlag-K436M and 3xFlag-S531N were injected
in mouse striatum at titers to obtain broad expression and
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co-injected with LV-eGFP at a low titer to label isolated
neurons for the subsequent morphological analysis (Fig-
ure S1a). The efﬁciency of the rAAV vectors in transducing
PAK6 variants at comparable levels in mouse striata was
tested by 3, 30-diaminobenzidine staining (Figure S1b). Six
striata were injected per condition and neuronal morphology
was analyzed on z-stack projections obtained by confocal
microscopy. In our system, neurite complexity is not changed
by the ablation of LRRK2 gene in adult striatum (Fig. 4c–d),
which contrasts to what is observed in primary cultures
(Dachsel et al. 2010). This suggests that the enhanced neurite
outgrowth phenotype observed in knock-out primary neurons
is presumably related to development more than maintenance
of neurites in the adult. Instead, we observed that expression
of PAK6 wild type results in a modest increase in neurite
length compared to control, whereas expression of the hyper-
active PAK6 S531N caused a signiﬁcant increase in wild-
type mice (Fig. 4c–e; p < 0.05, two-way ANOVA with
Tukey’s HSD post hoc test). Strikingly, PAK6 S531N is
no longer able to stimulate neurite outgrowth in LRRK2
knock-out neurons (Fig. 4d–e, two-way ANOVA with Tukey’s
HSD post hoc test). As control, we do not observe any
morphological changes between wild type and knock-out
striatal neurons transduced with PAK6 K436M.
Taken together, these results indicate that PAK6 kinase
activity enhances neurite length and complexity through
LRRK2.
LRRK2 regulates PAK6 activation in vivo
As the results presented so far suggest that PAK6 requires
LRRK2 to exert its function, we next investigated whether
LRRK2 can activate PAK6. To this aim, we ﬁrst tested the
ability of LRRK2 to stimulate PAK6 autophosphorylation
in vitro. 3xFlag-PAK6 wild type and S531N were puriﬁed
and either subjected, or not, to in vitro kinase assays. While
the S531N exhibits ~ 3-fold higher phosphorylation at S560
compared to wild type, as expected, both proteins were
unable to further autophosphorylate at this site in vitro
(Fig. 5a). This suggests that additional cellular components
are required to stimulate autophosphorylation of S560. We
then asked whether LRRK2 is sufﬁcient to trigger this
phosphorylation. 3xFlag-LRRK2 wild type, G2019S and
Fig. 3 PAK6 binds endogenous LRRK2
in vivo. (a) Striatal sections (50 lm) of
paraformaldehyde-perfused brains
sterotaxically injected with recombinant
adeno-associated viral (rAAV) encoding
3xFlag-PAK6 and 3xFlag-GFP and
incubated with anti-ﬂag antibody followed
by 3, 30-diaminobenzidine-peroxidase
staining. (b) Lysates from mouse striatum
injected with rAAVs encoding 3xFlag-PAK6
and 3xFlag-GFP were subjected to co-
immunoprecipitation using anti-Flag
antibody, followed by anti-Flag and anti-
LRRK2 (MJFF2) immunoblotting. Scale bar
1 mm.
Fig. 2 The Cdc42/Rac-interactive binding (CRIB) domain of PAK6
interacts with the ras of complex (ROC) domain of LRRK2. (a) The
ROC domain of LRRK2 is responsible for LRRK2-PAK6 interaction.
Cell lysates from stable HEK293T cells over-expressing PAK6 and
transfected with an empty vector (EV), Flag-tagged full-length LRRK2
or LRRK2 fragments were subjected to co-immunoprecipitation using
anti-Flag antibody, followed by anti-PAK6 and anti-Flag immunoblot-
ting. A schematic representation of the different LRRK2 fragments
used is shown below immunoblots. Blots are representative of three
independent experiments. * and ** indicate antibody heavy and light
chains, respectively. (b) Quantiﬁcation of PAK6 binding to LRRK2
domains. Data are representative of three independent experiments
and bars represent the mean  SEM. (c) Schematic of PAK6 domains
and amino acid sequence of CRIB domain. (d) GST-CRIB of PAK6
detects active Rac1. GST-CRIB and GST alone puriﬁed from bacterial
sources and bound to glutathione-sepharose resin were incubated with
cell lysates from HEK293T cells over-expressing 3xFlag-Rac1 in the
presence of GDP or non-hydrolyzable GTP. Samples were subjected
to immunoblotting using anti-Flag or stained with Coomassie. (e) PAK6
interacts with LRRK2 via CRIB. GST-CRIB and GST alone puriﬁed
from bacterial sources and bound to glutathione-sepharose resin were
incubated with cell lysates from HEK293T cells transfected with
3xFlag-LRRK2 in the presence of GDP or non-hydrolyzable GTP.
Samples were subjected to immunoblotting using anti-Flag or stained
with Coomassie. (f) Quantiﬁcation of Rac1 and LRRK2 binding to the
CRIB domain. Data are representative of three independent experi-
ments and bars represent the mean  SEM.
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Fig. 4 PAK6 and LRRK2 cooperate to control neurite growth in vivo.
(a) Schematic of PAK6 functional mutations. Auto-phosphorylation of
PAK6 at S560 is monitored by western blotting of striata injected with
PAK6 wild type, K436M and S531N probed with anti phospho-S560
and anti-PAK6 antibodies. (b) Quantiﬁcation of (a) from n = 4 injected
brains (bars represent the mean  SEM, unpaired t-test; *p < 0.05).
(c–d) Representative images of striatal neurons co-transduced with
recombinant adeno-associated virals encoding PAK6 wild type, S531N,
K436M or mCherry as control together with low titer LV-eGFP to label
individual neurons. Scale bar represents 50 lm. (e) Quantiﬁcation of
neurite length by two-way ANOVA with Tukey’s HSD post hoc test for all
variants (*p < 0.05). Data were collected from six injected striata per
condition. Twelve transduced neurons per condition were analyzed
(bars represent the mean  SEM).
© 2015 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2015) 135, 1242--1256
1250 L. Civiero et al.
K1906M were puriﬁed and incubated with 3xFlag-PAK6 in
the presence or absence of Mg2+ and ATP. Phosphorylation
of T2483 and T1491 (two LRRK2 autophosphorylation sites)
was monitored to conﬁrm that the kinase reaction worked
(Fig. 5b). Under this assay condition, we found that
autophosphorylation of PAK6 at S560 was not stimulated
by LRRK2 kinase activity (G2019S) or by LRRK2 itself
(K1906M) (Fig. 5b–c, p > 0.05 for all groups, one-way
ANOVA with Tukey’s HSD post hoc test). Altogether, these
results indicate that isolated LRRK2 is not able to activate
isolated PAK6 in vitro and that a more complex cellular
mechanism is likely required. To test this second hypothesis,
we monitored the activation status of the kinase in brain
lysates from LRRK2 wild type versus knock-out mice. While
we could not observe any difference in PAK6 autophospho-
rylation in 3-month-old brains (data not shown), a signiﬁcant
decrease in S560 phosphorylation was found in 12-month-
old LRRK2 knock-out compared to wild-type mice (Fig. 6a–b,
**p < 0.01, unpaired t-test).
To further investigate if the observed LRRK2-dependent
PAK6 activation has an impact on the downstream compo-
nents of the signaling pathway, we then compared the
phosphorylation status of a PAK6 substrate, LIMK1, in brains
from LRRK2 wild-type versus knock-out mice. LIMK1 is an
established downstream effector of the PAK family (Radu
et al. 2014), which plays a key role in the regulation of actin
polymerization through downstream phosphorylation of the
actin-severing protein coﬁlin (Yang et al. 1998). First, we
tested the ability of PAK6 to phosphorylate LIMK1 at
T508 in vitro. Recombinant 3xFlag-PAK6 wild type and
3XFlag-LIMK1 were puriﬁed and subjected to in vitro kinase
assay. As shown in Fig. 6c–d, PAK6 can efﬁciently phos-
phorylate LIMK1 at T508. We subsequently measured the
phosphorylation levels of LIMK1 at T508 in brain lysates
from LRRK2 wild-type and knock-out mice and observed a
signiﬁcant reduction of phospho-T508 in knock-out brains,
similar to what was observed for PAK6 S560 (Fig. 6e–f,
*p < 0.05, unpaired t-test).
Overall, these results suggest that LRRK2 is part of a
cellular complex required to activate the PAK6 pathway
in vivo.
PAK6 is aberrantly activated in post-mortem tissues from
PD brains
To investigate if PAK6 is aberrantly activated in pathological
conditions, we next measured PAK6 S560 phosphorylation
in G2019S and iPD brains. Western blot analysis shows that
phospho-PAK6 is increased in basal ganglia from iPD (n = 4
cases) as well as mutant G2019S LRRK2 (n = 3 cases) PD
patients of ~ 2-fold compared to age-matched healthy
controls (n = 4 cases) (Fig. 7a–b). These results were further
supported by immunohistochemistry of basal ganglia sec-
tions from iPD and G2019S LRRK2 patients versus controls
(Fig. 7c–d).
Taken together, these data support a functional interplay
between LRRK2 and PAK6 in the pathophysiology of
human PD and suggest that LRRK2 may exert its toxicity
through an aberrant regulation of PAK6 in PD.
Fig. 5 LRRK2 does not stimulate PAK6 auto-phosphorylation in vitro.
(a) PAK6 activation at S560 occurs in the cell. Recombinant 3xFlag-
PAK6 wild type and S536N were puriﬁed and subjected to kinase
assays in vitro with or without the addition of ATP-Mg2+. PAK6
activation and kinase activity were measured by monitoring S560 and
the incorporation of 33P, respectively. (b) PAK6 activation at S560 is
not regulated by LRRK2 in vitro. Recombinant 3xFlag-PAK6 alone or
together with 3xFlag-LRRK2 wild type, K1906M and G2019S in a 1 : 3
ratio was subjected to kinase assays in vitro with or without the addition
of ATP-Mg2+. The incorporation of 33P was monitored by western
blotting with anti phospho-S560 PAK6 and anti phospho-T2483/T1491
LRRK2 antibodies. (c) Quantiﬁcation of phospho-S560 by one-way
ANOVA with Tukey’s HSD post hoc test. Data were collected from three
independent experiments (bars represent the mean  SEM).
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Discussion
Mutations in LRRK2 are a common cause of PD; however,
the physiological function of LRRK2 and the molecular
mechanisms behind LRRK2-linked PD are still poorly
understood. One approach to gain insights into the func-
tion/dysfunction of a protein of interest is to elucidate its
interactome. Here, we reveal the functional nature of the
interaction between LRRK2 and PAK6, a novel LRRK2
partner identiﬁed using a protein array screening methodol-
ogy. We demonstrated that LRRK2 and PAK6, interacting
through their GTPase/ROC and CRIB domains, form a
functional complex in mammalian brain, which impacts
neurite outgrowth.
Fig. 6 PAK6 and LIMK1 activation are
impaired in LRRK2 knock-out mouse
brains. (a) PAK6 phosphorylation is
decreased in LRRK2 knock-out brains.
Lysates from LRRK2 three wild-type and
three knock-out mouse brains were
subjected to immunoblot using anti PAK6
and anti phospho-S560. (b) Quantiﬁcation of
phospho-S560 by unpaired t-test
(**p < 0.01). Data were collected
from three 12-month old-mouse brains
(bars represent the mean  SEM). (c)
PAK6 phosphorylates LIMK1 at T508.
Recombinant 3xFlag LIMK1 and PAK6
were subjected to kinase assays in a 5 : 1
ratio. The amount of phosphorylated LIMK1
was quantiﬁed by western blotting with anti
phospho-T508 LIMK1 antibody. (d)
Quantiﬁcation of phospho-T508 relative to
total LIMK1. Data were collected from three
independent kinase assays (bars represent
the mean  SEM). (e) LIMK1 phos-
phorylation is decreased in LRRK2 knock-
out brains. Lysates from LRRK2 three
wild-type and three knock-out mouse brains
were subjected to immunoblot using
anti-LIMK1 and anti anti phospho-T508
antibodies. (f) Quantiﬁcation of phospho-
T508 by unpaired t-test (*p < 0.05). Data
were collected from three 12-month old-
mouse brains (bars represent the
mean  SEM).
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PAKs comprise a family of serine-threonine kinases
playing a central role in signal transduction. In contrast to
class I PAKs (PAK1-3) which are activated by Rho GTPase
binding, class II PAKs (PAK4-6) are re-localized (not
activated) by GTPases within speciﬁc signaling sites and
locally activated by binding with SH3 domains to release
pseudo-substrate inhibition (Ha et al. 2012). One of the
best-characterized functions of these kinases is their role in
actin cytoskeleton reorganization, such as formation of
lamellipodia, ﬁlopodia, and membrane-rufﬂes via the LIM
kinase-coﬁlin pathway (Edwards et al. 1999). PAK5 and
PAK6 are highly expressed in the brain and, interestingly,
PAK5/PAK6 double knock-out mice display neurite short-
ening and learning and memory defects (Nekrasova et al.
2008).
In the nervous system, ﬁnely controlled neuronal connec-
tivity is fundamental for maintenance of brain architecture
and cognitive functions. Dynamic changes in actin cytoskele-
ton provide the mechanical force for neurite outgrowth,
synapse formation and neuronal migration. Accordingly,
defective cytoskeletal dynamics causes multiple neurode-
generative diseases (Heredia et al. 2006; Ma et al. 2012;
Saal et al. 2015). LRRK2 has been robustly linked to actin
dynamics: it impacts Erzin, Radixin, Moesin phosphorylation
in neurons (Parisiadou et al. 2009) and binds F-actin
modulating its assembly in vitro (Meixner et al. 2011).
Furthermore, phosphorylation of LRRK2 at S910/935 is
required for binding to 14-3-3 proteins, and LRRK2
dephosphorylation results in protein re-localization within
deﬁned intracellular sites including cytoskeletal-associated
structures (Dzamko et al. 2010; Nichols et al. 2010). To
explore the hypothesis of an interplay between LRRK2 and
PAK6 in a signaling network related to actin cytoskeleton
dynamics, we searched for a functional phenotype in vivo.
We found that over-expression of PAK6 in brain striata
increases neurite length in a kinase dependent manner.
However, when LRRK2 is knocked-out, PAK6 activity is no
longer effective, supporting the notion that LRRK2 is
required for PAK6-dependent regulation of neurite morpho-
genesis.
Rho GTPase-dependent neurite elongation and branching
are essential mechanisms for the formation of functional
networks connecting neurons through synapses, and its
deregulation may contribute to neurodegeneration (Heredia
et al. 2006; DeGeer and Lamarche-Vane 2013; Saal et al.
2015). Interestingly, LRRK2 has been previously suggested
to inﬂuence neurogenesis (Buchwald et al. 2001; Winner
et al. 2011) as well as pre-synaptic (Matta et al. 2012;
Cirnaru et al. 2014) and post-synaptic functions (Migheli
et al. 2013; Beccano-Kelly et al. 2014) and our results
identify PAK6 as possible mediator of LRRK2 activity
within these processes.
Fig. 7 Phospho-PAK6 levels are increased
in mutant G2019S LRRK2 and idiopathic
PD (iPD) brains. (a) Immunoblot of
endogenous phospho-S560 PAK6 levels in
basal ganglia lysates from human G2019S
LRRK2 Parkinson’s disease (PD) patients,
human iPD patients, and neurologic
controls. (b) Quantiﬁcation of phospho-
S560 PAK6 by one-way ANOVA with
Tukey’s post hoc test (*p < 0.05, iPD vs.
control). (c) Representative images of
phospho-S560 PAK6 staining in basal
ganglia from iPD, G2019S LRRK2 PD
patients and a control case. Scale bar
10 lM. (d) Semi-quantitative analysis of
phospho-S560 PAK6 immunoreactivity (IR)
in G2019S, iPD and control cases.
Phospho-S560 IR was assessed according
to a four-tired scoring system: score 0 = no
P-PAK6 IR, score + = weak P-PAK6 IR,
score ++ = moderate P-PAK6 IR, score
+++ = strong P-PAK6 IR.
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We collected additional evidence both from mouse and
human brain tissues supporting a mechanism where LRRK2
is important in the activation mechanism of PAK6. LRRK2
kinase activity is not sufﬁcient to directly activate PAK6
in vitro suggesting that complex cellular machinery is
required. Accordingly, we found that ablation of LRRK2
causes a signiﬁcant reduction of activated PAK6 in the brain
and a parallel decrease in the phosphorylation levels of the
PAK6 substrate LIMK1. Recently, LRRK2 was suggested to
function as a scaffold, compartmentalizing protein kinase A
via its ROC domain (Parisiadou et al. 2014). Together, our
ﬁndings support a similar scenario where the ROC domain of
LRRK2, in analogy to the Rho GTPases, re-localizes PAK6
during signaling (Ha et al. 2012).
Both LRRK2 and PAK6 are expressed in human brain
(Taymans et al. 2006; Nekrasova et al. 2008, Mandemakers
et al. 2012) and deregulation of the LRRK2-PAK6 signal-
ing because of LRRK2 mutations may affect neuronal
communication with consequent pathological outcomes. To
this regard, we found that PAK6 exhibits increased
autophosphorylation in G2019S and iPD brains, indicating
the presence of hyperactive PAK6 in sporadic and LRRK2-
linked PD. We speculate that overactive PAK6 owing to
mutant LRRK2 may result in deregulated actin cytoskeleton
dynamics via LIMK1 with impact on neurite growth and
synaptic activity. Our data may imply that overactive PAK6
owing to LRRK2 mutation is associated with increased
neurite outgrowth. However, it has been reported that the
G2019S induces neurite retraction (Parisiadou et al. 2009).
While it remains unclear whether the shorter neurite
phenotype linked to G2019S depends on its intrinsic higher
toxicity (Greggio et al. 2006; Smith et al. 2006) or to a
speciﬁc alteration of the signaling stimulating neurite
outgrowth, further investigation is clearly necessary to shed
light into the complex relationship among pathological
LRRK2, PAK6 activation and neuronal degeneration.
In conclusion, starting from a protein array screening, our
study reveals a novel functional interaction between LRRK2
and PAK6 in controlling neurite morphology and the
molecular characterization of this interaction disclosed
PAK6 as novel, explorable target for LRRK2-linked PD.
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